Diag723

Preclinical

Diag723 is one of 20 therapeutic programs targeting Hereditary Hemorrhagic Telangiectasia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Hereditary Hemorrhagic TelangiectasiaRecruiting

Hereditary Hemorrhagic TelangiectasiaPreclinical

Recruiting

Competition

Competitive Landscape

27 competitors in Hereditary Hemorrhagic Telangiectasia

#DrugCompanyPhaseTrials

Bactroban

PPadagis LLC

Approved

—2

Inderal

WWyeth-Lederle Vaccines

Avastin

7 4

Votrient

Novartis

Phase 2

2 5

Nolvadex

AstraZeneca

Phase 2

1 6

Thalomid

Bristol-Myers Squibb

Phase 2

1 7

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

2 8

Cyklokapron

AAmring

Phase 2

1 9

Sandostatin

Sun Pharma

Phase 2

1 10

Ofev

Boehringer Ingelheim

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Hereditary Hemorrhagic Telangiectasia

NCT07623525

Clinical

Trials by Indication[1]

Hereditary Hemorrhagic Telangiectasia1 trial

A Phase 1/2, First-in-Human, Multicenter, Ascending Single-Dose and Multi-Dose Study to Assess the Safety of DIAG723, a Novel Bispecific ALK-1 and BMPRII Agonist Antibody in Adult Patients With Hereditary Hemorrhagic Telangiectasia (DIAMOND Trial)

Recruiting·DDiagonal Therapeutics, Inc.·Preclinical·NCT07623525·93 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Diag723. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Diag723. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Diagonal Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: DDiagonal Therapeutics, Inc.

Diag723

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Hereditary Hemorrhagic Telangiectasia1 trial

References

Drug Info

Quick Facts

Related News